Patent intelligence · US
US 12005080
Method for promoting proliferation of immune cells
Method for promoting proliferation of immune cells
Patent details — US 12005080
- Jurisdiction
- US
- Status
- granted
- Grant date
- Jun 11, 2024
- Expiration
- Jun 6, 2044
- Applicant
- Oricell Therapeutics Co., Ltd.
- Claims
- 9
- CPC classes
- A61K, A61K2239/31, A61K2239/38, A61K2239/53
Quick answer
US 12005080 (Method for promoting proliferation of immune cells) is held by Oricell Therapeutics Co., Ltd.. Status: granted. Granted Jun 11, 2024. Expires Jun 6, 2044 (18 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Oricell Therapeutics Co., Ltd.
- Grant date
- Expiration
- Claims
- 9
- CPC classes
- A61K, A61K2239/31, A61K2239/38, A61K2239/53, A61K35/14, A61K40/11
More from Oricell Therapeutics Co., Ltd.
Related pharmaceutical patents in our USPTO index.
-
US 12312339
Polo like kinase 4 inhibitors
granted -
US 12239729
TRPV3 agonists for the treatment of skin conditions
granted -
US 12054556
Anti-PD-L1 antibody and use thereof
granted -
US 12018043
CD73 inhibitors
granted -
US 11993655
Anti-PD-L1 antibody and use thereof
granted -
US 11858915
Polo like kinase 4 inhibitors
granted -
US 11807658
CD73 inhibitors
granted
Frequently asked questions
What is US patent 12005080?
US 12005080 (Method for promoting proliferation of immune cells) is held by Oricell Therapeutics Co., Ltd.. Status: granted. Granted Jun 11, 2024. Expires Jun 6, 2044 (18 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 12005080?
Oricell Therapeutics Co., Ltd. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 52 pharmaceutical patents for this assignee.
When does US 12005080 expire?
Our index shows an expiration date of Jun 6, 2044 (18 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.